CDI / Georgetown – Postdoctoral Seminar Series
About the Series
Launched in 2020, this consortium-wide seminar series highlights research by our postdoctoral and clinical fellows.
2021-2022 Speakers
May 26, 2022
3:00 – 4:00 p.m.
Join via Zoom
Amir Arastehfar, PhD
Dr. David Perlin Lab
Title: “The Impact of Antifungal Drugs on the Intracellular Pathogenic Fungus Candida glabrata and the Influence of Drug Resistance on The Macrophage-Fungus Interaction”
Pradeep Ramalingam, PhD
Dr. Jason Butler Lab
Title: “Reactivation of DNA Damage Response Restores Blood Stem Cell Fitness During Aging”
December 2, 2021
3:00 – 4:00 p.m.
Join via Zoom
Michael T. Serzan, MD
Mentor: Michael B. Atkins, MD
Title: “Renal Cell Carcinoma: Striking at the Root”
Guannan Wang, MD
Mentor: Nanette Bishopric, MD
Title: “The APOE4 Allele Aggravates Doxorubicin Cardiotoxicity in Mice”
November 16, 2021
3:00 – 4:00 p.m.
Join via Zoom
Manpreet Bariana, PhD
Dr. Johannes Zakrzewski Lab
Title: “Targeting NF-κB in multiple myeloma with a small molecule inhibitor”
Jickky Sarathy, PhD
Dr. Thomas Dick Lab
Title: “Targeted protein degradation in mycobacteria”
2020-2021 Speakers
October 27, 2020
Megan Mitchell, PhD
Dr. Olivier Loudig Lab
Title: “Optimization of a versatile, high-purity exosome purification assay for biomarker discovery”
Dereje A. Negatu, PhD
Dr. Thomas Dick Lab
Title: “Human gut microbiota metabolite targets amino acid biosynthesis in Mycobacterium tuberculosis”
April 27, 2021
Kelly O’Neill, PhD
Dr. David Perlin Lab
Title: “Elucidating Molecular Heterogeneity Within the Glioblastoma Multiforme Tumor Microenvironment Using Matrix Assisted Laser Desorption/Ionization (MALDI) Mass Spectrometry Imaging (MSI)”
Uday Ganapathy, PhD
Dr. Thomas Dick Lab
Title: “A Leucyl-tRNA Synthetase Inhibitor with Broad-Spectrum Anti-Mycobacterial Activity”
May 12, 2021
Randi Williams, PhD
Mentor: Kathryn Taylor, Ph.D. and Lucile Adams-Campbell, Ph.D.
Title: ”Multilevel Approaches to Address Cancer Disparities in the Clinical Context”
Shaymaa Bahnassy, PhD
Mentor: Rebecca B. Riggins, Ph.D.
Title: ”Subclonal Hypermutation as a Potential Mechanism of Drug Resistance in HER2+/ER+ Breast Cancer”